All In MedTech

FDA Clearance Tracker · P050012-S017

THE DEXCOM SEVEN CONTINUOUS GLUCOSE MONITORING SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 3, 2008

Approved

Time to decision

71 days

Received Sep 23, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P050012-S017
Device name
THE DEXCOM SEVEN CONTINUOUS GLUCOSE MONITORING SYSTEM
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Sep 23, 2008
Decided
Dec 3, 2008
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P050012

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATIONS MADE TO THE RECEIVER SUB-COMPONENT PCBA AND HOUSING; MANUFACTURING PROCESSES OF THE RECEIVER TO ACCOMMODATE A REVISED PCBA; AND OUTSOURCING OF THE ALTERNATIVE RECEIVER MANUFACTURING PROCESS.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.